For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Vertex Pharmaceuticals Incorporated (VRTX) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Low · Gem Score -19 (−100…+100 Quality+Value blend) · Quality 50 · Value -76 · Sentiment 57 (timing only, not weighted) · Composite fair value $226.64 vs $484.03 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Vertex Pharmaceuticals Incorporated
VRTX NASDAQVertex Pharmaceuticals Incorporated is a global biotechnology company focused on discovering, developing, manufacturing, and commercializing transformative medicines for serious diseases. The company is best known for its leadership in cystic fibrosis, where it markets a portfolio of CFTR modulator therapies such as Trikafta/Kaftrio, Symdeko/Symkevi, Orkambi, Kalydeco and Alyftrek that address underlying genetic defects in eligible patients across multiple age groups. Beyond cystic fibrosis, Vertex today provides and develops treatments for sickle cell disease, transfusion-dependent beta thalassemia, and moderate-to-severe acute pain, as well as investigational therapies for APOL1-mediated kidney disease and other severe conditions. Headquartered in Boston, Massachusetts and founded in 1989, Vertex operates across the United States, Europe, and internationally, serving specialized markets through a combination of proprietary drug development, advanced research collaborations, and global commercialization capabilities. Its portfolio positions the company as a key player in specialty care within the broader healthcare and biotechnology sectors.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 15.32
Total Equity: $18.67B
Shares: 258,000,000
Total Debt: $0.00
Cash: $5.08B
EBITDA: $4.38B
Total Debt: $0.00
Cash: $5.08B
Revenue: $12.00B
Revenue: $12.00B
Revenue: $12.00B
Total Equity: $18.67B
Tax Rate: 14.9%
Equity: $18.67B
Total Debt: $0.00
Cash: $5.08B
Current Liabilities: $3.86B
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $18.67B
Shares: 258,000,000
Shares: 258,000,000
CapEx: -$437.60M
Shares: 258,000,000
Stock Price: $484.03
Net Income: $3.95B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 6, 2026 8:27am (17d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $7.6B | $8.9B | $9.9B | $11.0B | $12.0B |
| Cost of Revenue | $904.2M | $1.1B | $1.3B | $1.5B | $1.7B |
| Gross Profit | $6.7B | $7.9B | $8.6B | $9.5B | $10.4B |
| Operating Expenses | $3.9B | $3.5B | $4.8B | $9.7B | $6.2B |
| Operating Income | $2.8B | $4.3B | $3.8B | -$232.9M | $4.2B |
| Net Income | $2.3B | $3.3B | $3.6B | -$535.6M | $4.0B |
| EBITDA | $2.9B | $4.5B | $4.0B | -$25.7M | $4.4B |
| EPS | $9.09 | $12.97 | $14.05 | $-2.08 | $15.46 |
| EPS (Diluted) | $9.01 | $12.82 | $13.89 | $-2.08 | $15.32 |
Balance Sheet (Annual)
Last updated: Aug 5, 2026 9:41am (18d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $6.8B | $10.5B | $10.4B | $4.6B | $5.1B |
| Total Current Assets | $9.6B | $13.2B | $14.1B | $9.6B | $11.2B |
| Total Assets | $13.4B | $18.2B | $22.7B | $22.5B | $25.6B |
| Current Liabilities | $2.1B | $2.7B | $3.5B | $3.6B | $3.9B |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $3.3B | $4.2B | $5.1B | $6.1B | $7.0B |
| Total Equity | $10.1B | $13.9B | $17.6B | $16.4B | $18.7B |
| Retained Earnings | $3.2B | $6.5B | $10.1B | $9.6B | $13.6B |
Cash Flow (Annual)
Last updated: Aug 6, 2026 8:27am (17d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $2.6B | $4.1B | $3.5B | -$492.6M | $3.6B |
| Capital Expenditure | -$235.0M | -$204.7M | -$200.4M | -$297.7M | -$437.6M |
| Free Cash Flow | $2.4B | $3.9B | $3.3B | -$790.3M | $3.2B |
| Acquisitions (net) | $0 | -$295.9M | $0 | $0 | — |
| Net Debt Issued / (Repaid) | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$1.4B | $0 | -$427.6M | -$1.2B | -$2.0B |
| Net Change in Cash | $811.2M | $3.7B | -$139.7M | -$5.8B | $515.6M |
Growth Trends (YoY %)
Last updated: Aug 6, 2026 8:27am (17d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +17.9% | +10.5% | +11.7% | +8.9% |
| Gross Profit Growth | +17.7% | +9.6% | +10.3% | +9.1% |
| Operating Income Growth | +54.8% | -11.0% | -106.1% | +1,891.9% |
| Net Income Growth | +41.8% | +9.0% | -114.8% | +838.1% |
| EBITDA Growth | +53.2% | -9.9% | -100.6% | +17,154.9% |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-19 11:16Even the bull case prices 23% below today — the ratio here measures the model-vs-market gap, not payoff odds. Another quarter like the worst recent one costs 45%.
| Case | Growth | Margin | Fair value | vs price ($484.03) |
|---|---|---|---|---|
| Bull — recovery | +18% | 35.0% | $372.31 | -23% |
| Base — stabilizes | +12% | 35.0% | $308.21 | -36% |
| Bear — keeps slipping | +6% | 29.8% | $218.83 | -55% |
| Stress — last quarter repeats | +8% | 35.0% | $267.46 | -45% |
Narrative Economics
market-narrative step).
Claude Reading
Looking at the raw quarterly cadence first: revenue has stepped from $2.77B (Q3 2024) to $3.33B (Q2 2026) — that's ~20% over seven quarters, or roughly 10-11% annualized, matching the stated 10.3% CAGR. Net income margins are stable in the 33-37% band once you strip the 2025 Q1 dip (23.3%, likely a one-time IPR&D or Alyftrek-related charge) and the 2024 full-year GAAP loss (-$535M, driven by the $4.4B Alpine Immune acquisition writedown). Normalized, this is a ~$12B revenue, ~35% net margin, ~$3.2B FCF business with zero debt and $5B cash. That's a genuinely high-quality franchise. But FCF CAGR is *negative* 2.2% while revenue grew 10% — meaning working capital and R&D intensity are eating the incremental margin. That's a real flag the synthesis under-weighted.
At $484 and $122.7B market cap, you're paying 31.5x earnings and ~38x FCF for a business growing revenue 9% YoY with decelerating quarterly trend and flat-to-declining FCF. The synthesis DCF of $205 implies the market is paying ~$260/share (~$66B) purely for pipeline optionality — casgevy (sickle cell/beta-thal, slow launch, ~$50M quarterly and manufacturing-constrained), suzetrigine/Journavx (non-opioid pain, launched Jan 2025, early scripts disappointing vs bull-case), vanza-cel (T1D, early), and inaxaplin (APOL1 kidney). I think $205 is too punitive — it likely uses a discount rate that ignores the CF franchise's bond-like durability through the late 2030s under composition-of-matter and Alyftrek extensions — but $484 is also clearly stretched. Fair value on a sum-of-parts (CF at 12-14x sustainable earnings ≈ $280-320, plus risk-adjusted pipeline NPV of $60-100) lands me at $340-420. So I *partially* agree with the "overvalued" verdict but reject the magnitude.
Where I dissent from the prior stack: the Thesis Evaluation's -6 score and the Narrative layer's "2.4x DCF" framing are directionally right but treat the CF cash flow like it's terminal. Trikafta/Kaftrio patents run to ~2037 in key jurisdictions, Alyftrek (vanza-tri-tez) just launched with better dosing and extends the franchise, and ex-US penetration (especially the ~$1B+ opportunity in emerging Europe/LatAm still ramping) provides organic growth without needing pipeline wins. The bear case "CF penetration ceiling in 18-24 months" is overstated — it's true for US Trikafta but ignores conversion to Alyftrek at a slightly higher price point and geographic runway. Conversely, the bull-case leans on Journavx being a $5B drug; real-world Q2 2026 uptake suggests $500M-1B is more realistic given payer resistance and prescriber inertia around a novel non-opioid mechanism. Casgevy is a scientific triumph and a commercial slog — $200-400M peak, not the multi-billion figure baked into consensus.
Contrarian read a careful skeptic would push: insider activity shows *sales* (three separate S-sales in early July 2026) with only routine award grants — no open-market buying by anyone who sees $205 or $340 as intrinsic. The negative FCF CAGR alongside positive revenue growth suggests the pipeline is consuming cash faster than the franchise generates incremental margin — classic late-stage-biotech capital intensity that markets historically de-rate. Weak Cash Flow Quality flag deserves more attention than any model gave it. Macro headwinds (IRA drug pricing negotiation exposure starting 2027-2028 for Trikafta as it crosses eligibility thresholds) is a real overhang nobody quantified. And the classification as "mature_earner" is arguably wrong — this is a *transition-stage* biotech trying to become a platform, which is a much harder valuation problem than either the mature-earner or platform-monopoly framing captures. Data thinness: no debt figure shown, no segment breakdown of Journavx/Casgevy revenue, and the "Market Forces" module failed entirely — so we're flying without competitive dynamics input on Sarepta, CRISPR Tx, and Journavx competitors.
Net: I agree VRTX is overvalued at $484 but the $202 synthesis fair value is a strawman that ignores CF durability and pipeline optionality with any positive expected value. My range is $340-420, call it $380 midpoint — meaning ~20% downside, not 58%. Not a short (franchise is real, balance sheet is fortress, pipeline has non-zero shots), not a buy (paying full price for optionality with decelerating FCF and insider selling). Wait for either a pipeline data-driven pullback into the $380s or a Journavx/Casgevy inflection that justifies the premium.
GPT Reading
Vertex is being valued less like a mature cash-generating biotech and more like a de-risked multi-franchise compounder, and the financials do not yet support that leap. The core business is excellent: revenue has grown from $7.57B in 2021 to $12.00B in 2025, gross margin is a superb 86.2%, and 2025 net income rebounded to $3.95B after the ugly 2024 loss year. Quarterly execution is also steady, with revenue rising from $2.77B in 2025-03 to $3.33B in 2026-06 and net margins back in the low-to-mid 30s. But the key point is that this is now a very large company growing at a high-single-digit pace, not an early-stage biotech inflecting into hypergrowth. The latest quarter’s 8.9% yoy revenue growth and the longer-run 10.3% revenue CAGR are solid, yet earnings CAGR is only 4.5% and FCF CAGR is negative at -2.2%. At $122.7B market cap, investors are paying about 10.4x sales, 31.6x earnings, and 26.9x EV/EBITDA for a business whose current economic engine still appears heavily concentrated and whose cash generation has not compounded in line with the equity value.
What stands out most is the mismatch between accounting recovery and valuation exuberance. 2024 produced an operating loss of $232.9M and a net loss of $535.6M, then 2025 snapped back to a 34.8% operating margin and 32.9% net margin on $12.0B of revenue. That tells me the franchise is resilient, but it also tells me reported profitability can swing materially based on spending and one-time charges; this is not a utility-like earnings stream deserving any price. Even after the recovery, 2025 operating cash flow was $3.63B and free cash flow $3.19B, implying the stock trades around 38x trailing FCF. For a debt-free company with $5.08B of cash, balance-sheet risk is negligible, but that cash hoard is not big enough to justify the premium by itself. If I look at the business as a dominant rare-disease franchise with modest organic growth, elite margins, and substantial but still unproven pipeline optionality, I do not get to nearly $484 without assuming multiple large pipeline wins are already substantially in the bag.
The strongest bull case is straightforward and not trivial to dismiss: Vertex is one of the few biotechs that has actually built a fortress franchise, not just promised one. Return metrics are excellent, with ROIC at 26.2% and ROE at 21.2%, there is no debt, and quarterly net income has stabilized above $1.0B in each of the last four quarters. Annual revenue grew nearly $1.0B in 2025, and the quarterly run-rate has now reached over $13B annualized if the latest quarter is sustained. A smart bull would say the market is right to capitalize this stream at a premium because the downside is cushioned by the existing franchise while the upside from new launches is meaningful and asymmetric. They would also argue that using 2025 FCF or earnings understates normalized power because this is a company that deliberately reinvests and can harvest margin if it wants to. That argument has force: if Vertex can convert its pipeline into even one additional multi-billion-dollar asset, 31x earnings may not look crazy in hindsight.
I still weigh the other side more heavily because the current multiple leaves too little room for the gap between “possible” and “commercially realized.” On the numbers we have, revenue growth is decelerating into the high single digits, FCF quality is flagged weak, and the company is already capitalized at more than 30 times earnings despite being past the phase where the base business can plausibly double quickly on its own. The market cap implies years of sustained compounding from a company whose 2025 free cash flow was only $3.19B and whose earnings progression has been less smooth than the stock’s premium suggests. Even if I grant that Vertex deserves to trade well above the average large-cap biotech because of its balance sheet, margins, and franchise durability, a fairer range looks more like a high-20s multiple on normalized earnings or low-30s multiple on FCF only if growth reaccelerates. On today’s fundamentals, that points materially below the current quote, not catastrophically lower like some hard-model outputs imply, but still clearly lower.
What would change my mind is evidence that the business is genuinely becoming a second-act growth story rather than a superb single-franchise compounder with expensive optionality. Specifically, I would want to see revenue growth reaccelerate from ~9% into the mid-teens while maintaining net margins above 33%, annual free cash flow move decisively above $4.5B, and at least a few quarters showing that post-launch non-core revenue is becoming large enough to matter against a $12B base. If the next 12-18 months produce that combination, then $484 can be defended and potentially surpassed. If instead revenue stays in the high-single-digit range and FCF remains around $3-4B, the stock is too expensive and likely deserves a valuation closer to $350-$400 than to $500.
Grok Reading
The raw numbers describe a high-quality cash compounder that has already matured. Vertex grew revenue from $7.57B in 2021 to $12.00B in 2025 at a 10.3% CAGR, with the latest quarter printing $3.33B and a 33% net margin—implying a ~$13.3B run-rate and roughly $4.4B of annualized earnings. Gross margin sits at 86%, operating margin 35%, ROIC 26%, and the balance sheet is fortress-clean: zero debt, $5.08B cash, $3.19B free cash flow. Those are elite industrial metrics, not speculative biotech ones. Yet the growth engine is visibly decelerating—recent revenue YoY is 8.9%, earnings CAGR over the period is only 4.5%, and FCF CAGR is negative. The 2024 operating loss and net loss of $536M was a one-time aberration (almost certainly collaboration/milestone accounting around the cell-therapy launch); 2025 snapped back to $3.95B of net income. The story the numbers tell is simple: a single dominant CF franchise still expanding mid-to-high single digits with extraordinary incremental margins, funding everything else, while the market capitalizes that stream at 32x earnings, 10.4x sales and 9.8x EV/revenue.
That capitalization is the problem. At $484 and a $123B enterprise, free-cash-flow yield is ~2.6%. The quantitative models’ $202–206 fair-value anchor is directionally correct even if too austere: strip out pipeline optionality and the Trikafta/Kaftrio cash flows alone support something in the low-to-mid $200s. The residual $250+ of market value is pure narrative premium on Casgevy (exagamglogene autotemcel), the non-opioid pain program VX-548, and the APOL1 kidney asset reaching multi-billion peak sales at high probabilities. Nothing in the reported P&L yet shows a second franchise contributing material revenue; the company remains a CF royalty stream with an expensive R&D call option attached. Insider activity is noise—small awards and routine sales—and FCF quality is already flagged weak, consistent with heavy reinvestment that has not yet produced visible top-line diversification.
The strongest counter-argument is that 32x is not outrageous for a monopoly-like asset with 86% gross margins, zero leverage, pricing power, and a clinically superior standard of care that patients cannot easily leave. Bulls will correctly note that Casgevy is already approved, early commercial traction exists, VX-548 addresses a vast untreated pain market, and Vertex has repeatedly executed on complex science. If the pipeline converts even one program into a $5B+ franchise by 2029–30 while CF continues to grind mid-single-digit growth plus label expansions, today’s multiple compresses into the mid-20s on 2028–29 earnings and the stock can compound from here. That case is coherent; I simply assign lower probabilities and lower peak-sales haircuts than the market. Manufacturing scale, payer friction, and competitive entry in cell/gene therapy remain under-appreciated risks, and CF penetration ceilings are real within a couple of years. The 139% premium to DCF therefore embeds success that is still several years and several binary events away.
I would flip to neutral or constructive on two concrete developments: (1) quarterly revenue re-accelerating above 12–15% sustained, proving either material CF upside or early pipeline contribution large enough to move the needle, and (2) Casgevy or VX-548 delivering clear multi-hundred-million run-rate revenue with expanding margins inside the next four to six quarters, converting narrative into reported numbers.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Vertex runs at biotech-elite gross margins (86-88% consistently 2021-2025) on a revenue base that has grown from $7.57B to $12.00B, a ~12% revenue CAGR. The balance sheet is a fortress: $6.61B net cash, Altman Z of 12.64, and self-funding via $3.19B trailing FCF. Earnings quality checks are clean (OCF/NI 1.04x, accruals -1.1%, Beneish -2.19), and diluted share count has actually shrunk slightly (-0.2% CAGR) with buybacks at 174% of the 5.7% SBC/revenue burden - disciplined per-share stewardship. Insider activity is small routine sales against awards, not directionally meaningful. However, 2024 stands out sharply: operating margin swung from +38.8% in 2023 to -2.1%, net income to -$535.6M, and FCF to -$790.3M, before snapping back to 34.8% OpM and $3.95B net income in 2025. That looks like a large one-time charge (likely an IPR&D writeoff from an acquisition given the pattern), not operational decay - 2025 confirms the underlying earnings power - but it flags that the P&L can be lumpy and R&D/M&A intensity is high. The core CF franchise (Trikafta/CF portfolio) throws off enormous cash, but the module flag of 'Weak Cash Flow Quality' plus that 2024 dislocation warrants scrutiny of franchise concentration and pipeline dependency.
Verify before trusting this (5)
- Nature of the 2024 charge that drove OpM to -2.1% and net income to -$535.6M (likely acquired IPR&D writeoff - which deal?)
- Revenue concentration: what % of 2025 $12B revenue comes from the CF franchise (Trikafta and related) vs newer products (Casgevy, Journavx)?
- Why the e2e context labels FCF quality as 'weak' when OCF/NI is 1.04x - working capital, tax, or capitalized development spend dynamics?
- Pipeline dependency and patent runway on the CF franchise
- Are the 2024 outflow and 2025 rebound distorted by acquisition accounting, and what does normalized FCF look like?
The composite fair value lands at $205.77 (signal-adjusted $202.29) against a $484.03 price, implying about -58% downside. Even the most generous anchor, an anchored-PE of $335.79 that already extrapolates a normalized earnings power, sits ~31% below the tape. The EPV floor of $116 says the CF cash engine on its own is not close to justifying today's cap of $123B. So the ~$280 per share above deserved value is effectively the market capitalizing Casgevy, the vanza/pain franchise, APOL1, and the diabetes cell program at peak-case outcomes years before commercial proof.
Verify before trusting this (5)
- Casgevy patient starts and revenue ramp per quarter - the single biggest swing factor on pipeline value
- Vanza/suzetrigine launch trajectory and payer coverage - non-opioid pain TAM is the bull case
- CF franchise revenue durability and any LOE/biosimilar signals into the 2030s
- R&D spend intensity and whether 2024's operating loss recurs - tells you the true steady-state earnings power
- Guidance on peak sales assumptions embedded in sell-side models
The dominant force on VRTX right now is a freshly reinforced platform-monopoly narrative: Q2 print beat on revenue, management raised 2026 sales guidance, and both UBS and RBC pushed out constructive notes within 48 hours framing the stock as well-positioned into a dense H2 catalyst calendar (kidney disease, cell/gene programs). That is textbook tailwind flow - the story is not just intact, it is being actively retold by sell-side into a market that is mildly risk-on. News on 8/4 explicitly frames VRTX as 'regaining its footing,' which tells you the tape had been softer and is now inflecting up. The macro backdrop is a secondary factor here. With beta 0.31, VRTX barely registers the S&P tape either way; the mildly risk-on regime and elevated 10y (4.63%) neither help nor hurt this defensive biotech meaningfully. What matters is that biotech-specific narrative flow is favorable and analyst tone is unambiguously positive coming out of the print. The counterweight is that the narrative durability is only 'moderate' and the bear case (patent cliff, pipeline priced-in) is real - but nothing in the last 72h news flow is feeding that bear thread. Net: a real, visible tailwind, but not a decisive one, because low beta also caps the upside push from any broad risk-on impulse.
Verify before trusting this (4)
- H2 2026 kidney disease (APOL1) readout tone and timing
- Any downgrade or target cut from a major sell-side shop that would break the unanimous positive post-Q2 chorus
- Sickle cell (Casgevy) commercial launch pace commentary in coming weeks
- Biotech sector rotation - XBI relative strength vs S&P as a proxy for narrative support
This lens hasn't been run for this ticker yet.
When we made this prediction on Aug 7, 2026, VRTX was $484.03. We expect it to be $448.00 by Feb 2027, and we consider it great value under $300.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 7, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.